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1. ABSTRACT 
 
 Melanoma probably is the most aggressive cancer 
in humans and remains one of the leading causes of cancer 
death in developed countries. This review summarizes the 
most important alterations in protooncogenes and tumor 
suppressor genes that contribute to the pathogenesis of 
malignant melanoma, with a special emphasis on the 
involved signaling pathways. Our knowledge of the 
molecular biology of melanoma has been benefited from 
recent advances on high-throughput technologies analyzing 
wide genomic and gene expression profiles that have 
uncovered unknown candidate genes. To test the 
interactions between distinct pathways and of those with 
the environment a wealth of genetically modified animal 
models has been generated over the past years. Other 
studies have focused on the isolation of melanoma stem 
cells and on the characterization of signaling pathways that 
contribute to their survival and maintenance. A 
consequence of all these studies is the emergence of 
potential new strategies that could improve the still 
unadequate arsenal of therapeutic tools to fight against this 
fatal disease.  
 
 
 
2. INTRODUCTION 
 
 The incidence of melanoma is rising by 3-8% per 
year in the Caucasian population (1). This fact together 
with the lack of remarkable therapeutic improvements 
represents a relevant health problem throughout the world. 
Melanomas derive from melanocytes, the pigment 
producing cells that mainly reside in the skin, although they 
can also arise from melanocytes residing in non-cutaneous 
tissues, such as the pigmented layer of the eye that includes 
the iris, ciliary body and chroids (uveal melanoma) or 
internal mucosal membranes (mucosal melanoma). 
Exposure to the sun is widely accepted as a major causative 
factor for melanoma development. Both UV components of 
sunlight: UVA (320-400 nm) and the UVB (290-320 nm) 
appear to be involved in the genesis of melanoma (2). Most 
of UVB light is absorbed by the ozone, but 5-10% of it 
reaches the earth surface. The exposure to UVB radiation 
leads the formation of pyrimidine pyridine photoproducts 
and cyclobutane pyrimidine dimer, whose incorrect repair 
leads to DNA mutations (C to T and CC to TT transitions). 
On the other hand, UVA genotoxicity is principally due to 
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Figure 1. Development of malignant melanoma. Metastatic melanoma is thought to arise by a multi-step process from precursor 
lesions such as benign nevus or dysplastic nevus. RGP, radial growth phase; VGP, vertical growth phase. 
 
indirect mechanisms mediated by reactive oxygen radicals 
(3). Melanin is the pigment synthesized within 
melanosomes in melanocytes; in the skin it acts as a filter 
by absorbing solar radiation.  
 
There are some paradoxes, however, regarding to 
the role of UV in the genesis of melanoma. In contrast to 
other common skin tumours, such as squamous cell 
carcinoma, melanoma results from intense rather than 
cumulative sun exposure, particularly during childhood (2, 
4). Thus, melanoma arises most commonly on the trunk, 
arms and legs than on areas that are chronically exposed to 
the sun, such as the face. In addition, there is no obvious 
linkage between UV irradiation and tumours arising in the 
palms of the hands and the soles of the feet (acral 
melanoma) or in mucosal membranes. Cutaneous 
melanoma has been classified into several histopathological 
stages: superficial spreading is the most common form of 
melanoma in Caucasians, lentigo malignant melanoma 
generally occurs on chronically exposed skin of the elderly, 
acral lentiginous melanoma is the predominant form of this 
disease in individual with darker skin, and nodular 
melanoma is characterized by the vertical growth of 
transformed melanocytes (5, 6). However, this 
classification is controversial since a substantial number of 
melanomas do not fit these types and, therefore, it has not 
been universally adopted in clinical practice (6-8). Five 
sequential steps (9) describe the histological changes that in 
most cases accompany the progression from normal 
melanocytes to metastatic melanoma: common acquired 
and congenital nevi without dysplasia (benign nevi), 
dysplastic nevi, radial-growth phase (RGP) melanoma, 
vertical-growth phase (VGP) melanoma and metastatic 
melanoma (Figure 1). Alternatively, RGP or VGP 
melanomas may arise direct from a skin without a previous 
benign or borderline melanocitic lesion. In all cases, it is 
believed that the crucial step in the evolution of malignant 
melanoma is the transition from RGP to VGP melanoma 
since, unlike RGP melanomas, VGP melanomas can 
undergo anchorage-independent growth and have acquired 
metastatic competence (10).  
 
3. SUSCEPTIBILITY GENES 
 
The most significant risk factor for melanoma 
occurs in individuals with a familial melanoma history. In 
families with multiple cases of melanoma, the pattern of 
susceptibility is consistent with the inheritance of 
autosomal dominant genes with incomplete penetrance, and 
the number of tumors developed might be determined by 
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the interaction of several factors: the presence of a 
hereditary susceptibility, sun exposure and other genes that 
mitigate the response of the skin to the sun, such as the 
melanocortin-1 receptor gene (MC1R) (11). Two genes 
have been found to be associated with high-penetrance 
susceptibility: CDKN2A, the most prevalent in families 
with melanoma, and CDK4. Nevertheless, it is well known 
how physical characteristics, such as fair-skin, red or blond 
hair, the inability to tan and a freckling phenotype, 
correlate with increased risk for melanoma development. 
Since certain MC1R polymorphic variants are associated 
with these characteristics and with a diminished ability of 
the epidermis to respond to UV damage, this pigment 
regulating gene is seen as a low-penetrance melanoma 
susceptibility gene (12-14). Co-inheritance of these MC1R 
variants increases the penetrance in CDKN2A families (15, 
16). A predisposition to skin cancer is also associated with 
the rare hereditary syndrome xeroderma pigmentosum 
(XP). Individuals with XP carry a nucleotide excision DNA 
repair defect associated with an acute photosensitivity. The 
most significant characteristic of XP patients is a 
predisposition to develop multiple skin cancers, mostly 
squamous cell carcinomas but also basal cell carcinomas 
and malignant melanomas (17). 
 
3.1. The CDKN2A locus and familial melanoma 
 Familial melanomas represent about 8-12% of all 
melanoma cases. The first melanoma susceptibility gene, 
CDKN2A, was identified at a locus at 9p21 by linkage 
analysis studies of families with high melanoma incidence 
(18, 19). CDKN2A encodes two unrelated proteins: 
p16Ink4a and p14Arf (the homologous of p19 Arf in mice) 
by a combination of alternative splicing and reading frames 
(Figure 2A). Both CDKN2A products are potent tumor 
suppressors involved in cell cycle regulation. p16Ink4a 
inhibits G1 cyclin-dependent kinases Cdk4/Cdk6-mediated 
phosphorylation of the retinoblastoma protein (pRb), 
arresting cell cycle progression through G1-S (20), whereas 
p14Arf favours apoptosis and blocks oncogenic 
transformation by stabilizing p53 levels through inhibition 
of Mdm2-mediated p53 ubiquitination (21-24). Hence, the 
loss of p16Ink4a function promotes hyperphosphorylation 
and inactivation of pRb, while loss of p14Arf inactivates 
p53, both leading to unrestricted cell cycle progression 
(Figure 2B). 
 
Germline CDKN2A mutations have been found 
up to 40% of families with 3 or more members affected by 
the disease and in 10% of families with 2 affected 
members. They are constituted by missense mutations of 
exons 1alpha, exon 2, the 5’ untranslated region and introns 
(see ref. 25 for review). As p16INK4A shares exon 2 with 
p14ARF (see Figure 2A), many CDKN2A mutations affect 
both proteins confounding the effective role of each gene in 
the melanoma genesis. Mutations affecting only p14ARF 
have been described in some melanoma families (26-28); 
this findings supports the role of p14ARF as a melanoma 
susceptibility gene independent of p16INK4A. In addition, 
genetically mouse models have provided convincing 
evidence that both p14ARF and p16INK4A are tumor 
suppressor genes in melanoma development (see below).  
 
The penetrance of CDKN2A is incomplete and 
shows variations between continents, countries and 
populations (11, 29). Thus, not all individuals carrying 
germline CDKN2A mutations will develop a melanoma. 
The presence of large numbers of pigmented lesions, 
including benign or clinically atypical nevi, known as 
familial atypical multiple mole-melanoma syndrome or 
atypical mole syndrome (FAMM or AMS, respectively) is 
associated with an increased risk to develop melanoma 
(30). However, FAMM cannot be used to predict gene-
carrier status in families with germline CDKN2A mutations, 
and, although the presence of FAMM increases the 
probability of melanoma in families, melanoma occurs in 
individuals who do not have FAMM (11). Some families 
carrying CDKN2A mutations also seem to be at increased 
risk of pancreatic cancer (31, 32). However, the precise 
relationship between pancreatic cancer and the CDKN2A 
locus remains elusive. Some authors have proposed that the 
type of mutation in CDNK2A affects risk of pancreatic 
cancer (33). 
 
A second melanoma susceptibility gene, CDK4, 
was found at chromosome 12q14 (34-36). Germline and 
sporadic mutations in CDK4 abrogating binding of Cdk4 to 
p16Ink4a (see Figure 2B) have been found associated with 
melanoma pathogenesis. Conversely, a mutation affecting 
exon 1alpha of p16INK4A impairing binding of p16Ink4a 
protein to Cdk4, but not Cdk6, has been recently reported 
(37). These results suggest that Cdk4 and Cdk6 are not 
functionally redundant, and emphasize the importance of 
CDK4 for the development of melanoma.  Thus, mutations 
in this gene have a similar impact to those in p16INK4a, 
and the phenotypic characteristics of families carrying 
germline CDK4 mutations do not differ from those families 
affected in the CDKN2A locus (38, 39). Consistent with the 
human data, mice expressing a mutant form of Cdk4 are 
predisposed to develop melanoma after carcinogen 
treatment (40). Moreover, evidence that links the entire 
p16Ink4a-Cdk4/Cdk6-pRb pathway to melanoma is the 
observation that hereditary retinoblastoma patients with 
germline inactivation of the retinoblastoma gene (RB1) are 
predisposed to melanoma (41, 42). 
 
Not all families with multiple cases of melanoma 
have identifiable CDKN2A or CDK4 mutations, and, 
therefore, other high-penetrance susceptibility genes remain 
to be identified. For example, there is evidence for another 
as yet unidentified melanoma susceptibility gene at 
chromosome 1p22 (43, 44).  
 
3.2. Melanocortin receptor 1 and the regulation of 
pigmentation 
 When the alpha-melanocyte-stimulating hormone 
(alpha-MSH) binds to its seven-transmembrane G-protein-
coupled receptor MC1R, which is present in epidermal 
melanocytes, it triggers an intracellular signaling pathway 
that is considered the most important regulator of 
pigmentation (25). This pathway involves activation of 
adenylate cyclase and production of cyclic AMP (cAMP). 
Elevated cAMP levels leads to phosphorylation and 
activation of the cAMP responsive element binding 
(CREB) family of transcription factors (Figure 3A). A 
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Figure 2. The CDNK2A locus. (A) Both p16Ink4a and p14Arf proteins are encoded by the CDNK2A gene. Each protein has a 
unique first exon (E1beta or E1alpha) that splices to a common second and third exon but in alternating reading frames. (B) 
p16Ink4a binds directly to cyclin-dependent kinases Cdk4 and Cdk6 blocking the assembly of catalytically active cyclinD-Cdk 
complexes. By phosphorylating members of the pRb family, these Cdk complexes enable the transcription of genes that are under 
the control of the E2F family of transcription factors. Elevated expression of p16Ink4a causes a G1-phase cell cycle arrest that is 
dependent on functional pRb. p14Arf stabilizes and enhances p53 level by inhibiting Mdm2-mediated p53 ubiquitination and 
degradation through the proteasome. p53 accumulation leads to either cell cycle arrest or apoptosis. 
 
critical CREB target gene is that encoding the 
microphthalmia associated transcription factor (Mitf) (45, 
46), a basic helix-loop-helix leucine zipper (b-HLH-Zip) 
factor that in turn regulates the transcription of genes 
encoding enzymes that are essential for melanin synthesis, 
such as tyrosinase, tyrosinase-related protein-1 (TRP-1) 
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Figure 3. (A) The MC1R signaling pathway. Binding of alpha-MSH to MC1R activates adenylate cyclase (AC) through a 
heterotrimeric G-protein complex. AC catalyzes the production of cAMP which leads to the phosphorylation of members of the 
CREB family of transcription factors. Activated CREB recruits CBP/p300 coactivators triggering transcriptional activation of 
multiple genes. MITF is a critical CREB target gene in melanocytes. Mitf can be phosphorylated by several kinases; i.e., 
extracellular-regulated kinase (Erk), ribosomal S6 kinase (RSK), GSK3beta, and p38MAPK. Activated Mitf regulates genes 
involved in pigmentation and differentiation. (B) Biochemical pathways leading to the synthesis of melanins. TRP-1, tyrosinase-
related protein 1; DCT, dopachrome tautomerase (also called TRP-2). 
 
and dopachrome tautomerase (DCT) (Figure 3B). MC1R is 
highly polymorphic in the human population. Some MC1R 
variants are associated with the Red Hair Color (RHC) 
phenotype, characteristic of individuals with red hair, fair 
skin, resistance to tan and freckle tendency. These 
individuals synthesize increased amounts of the potentially 
dangerous pheomelanin (reddish-yellow pigment) instead 
of the protective, photoreactive black-brown pigment 
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eumelanin (Figure 3B). In addition to its diminished UV-
light protective capacity, pheomelanin produces cytotoxic 
and mutagenic metabolites and presumably contributes to 
increase melanoma risk (12, 13, 25). In general, those 
MC1R variants that produce weak or absent cAMP 
response to alpha-MSH signals are associated with the 
RHC phenotype (47) and, therefore, they can be classified 
as low-risk melanoma susceptibility genes. 
 
 Although the current evidence supports the idea 
that sun exposure is causal for melanoma, the nature of the 
exposure appears to be also an important factor. Melanoma 
occurs most frequently after intermittently sun exposure 
and in individuals with frequent sunburns. Indeed, some 
epidemiological studies suggest that chronic sun exposure 
may protect individuals against melanoma (48). However, 
this is controversial as other studies support the view that 
cumulative sun exposure is a risk factor for melanoma 
(reviewed in ref. 11). Some authors have proposed that the 
effect of sun exposure might be lower in families with 
high-penetrance susceptibility genes than in those with 
low-penetrance susceptibility genes (49). 
 
4. GENETIC ALTERATIONS FOUND IN SPORADIC 
MELANOMA 
 
Despite its important role in melanoma 
predisposition, single mutations in the CDKN2A locus are 
rarely found in sporadic primary melanomas.  However, 
deletions of 9p, where CDNK2A is located, occur in 50% of 
sporadic melanomas, as found in a genome-wide analysis 
of chromosomal alterations (see below). Furthermore, a 
recent study has reported biallelic CDKN2A deletions in 
about 45% of melanoma metastases, emphasizing a role of 
this locus in melanoma progression (50). Some reports 
have found silencing of p16INK4A due to promoter 
hypermethylation in 19% of primary cutaneous melanomas 
and in 33% of the corresponding metastases (51). A higher 
frequency for p16INK4A promoter hypermethylation (33%) 
has been reported for uveal melanoma (52). In many cases, 
tumors are heterogeneous showing both methylated and 
unmethylated tumor cells (52, 53). In contrast to primary 
tumors, CDKN2A mutations are found frequently in 
melanoma cell lines (reviewed in ref. 39), a fact likely 
reflecting a selective event imposed by cell culturing due to 
the critical role of p16Ink4a in senescence, as cells that lose 
p16Ink4a escape senescence and become immortalized. 
 
As the gene encoding p53 (TP53) is the most 
frequent tumor suppressor inactivated in human cancer, it is 
surprising that the proportion of primary and metastatic 
melanomas containing mutations in TP53 is consistently 
low. Although UV light-related TP53 mutations are 
frequently observed in other skin tumors, such as basal and 
squamous cell carcinomas (17, 54), the above observation 
suggests that UV-induced mutational inactivation of p53 is 
not involved in melanoma formation. As p14Arf and p53 
are within the same pathway (see Figure 2B), the low 
frequency of p53 mutations in melanoma can be partially 
explained by the loss of p14Arf, via 9p21 deletion, which 
results in inactivation of the p53 pathway (25, 55). 
However, there is convincing evidence suggesting p53-
independent functions for Arf in a variety of cellular 
processes, including DNA-damage and apoptosis (56). 
Thus, a recent report using a genetically engineered mouse 
model has provided experimental evidence demonstrating 
that p19Arf, and not p53, acts as a suppressor of melanoma 
formation by inducing senescence in melanocytes (57).  
Strikingly, melanomas from XP patients with defective 
nucleotide excision repair (NER) pathway show a high 
TP53 mutation frequency of > 50% (17). It should be of 
interest to know whether CDKN2A gene alterations exist in 
XP melanomas, as there is no published report in this 
respect. Interestingly, abrogation of NER combined with 
Cdkn2a inactivation in a genetically engineered mouse 
model can drive melanomagenesis induced by a single, 
neonatal, UVB exposure (58). Besides pRb and Arf/p53, 
genetic and molecular studies have identified several 
important molecules and signaling pathways whose altered 
regulation appears to be crucial for the development of 
melanoma, as set out immediately below. 
 
4.1. Receptor tyrosine kinases 
c-Met is a receptor tyrosine kinase involved in the 
growth, invasion and metastasis of cancer cells.  The 
natural ligand of c-Met is the hepatocyte growth 
factor/scatter factor (HGF/SF), a multifunctional cytokine 
that acts as a mitogen, motogen and morphogen for 
epithelial cells. In normal skin, c-Met is expressed in 
keratinocytes and melanocytes, whereas HGF/SF is 
secreted mainly by mesenchymal cells within the dermis 
(59).  Several studies support the view that an autocrine 
HGF/SF/c-Met signaling loop is involved in the 
development of melanoma (60). Increased expression of c-
Met has been observed in metastatic melanoma (61, 62), 
and gain of the 7q33-qter locus (where c-MET is located) 
has been correlated with late stages of melanoma 
development (63, 64). In addition, a recent report describes 
the presence of c-MET activating mutations in some 
melanoma cell lines and tumor tissues (65). Melanoma 
cells, but not melanocytes, produce HGF/SF, which can 
induce sustained activation of its receptor (60). The cell-
cell adhesion protein E-cadherin mediates the association 
between keratinocytes and melanocytes within the basal 
layer of the epidermis, and these contacts inhibit 
melanocyte proliferation and suppress the expression of 
melanoma markers (66, 67). Besides to stimulate 
melanocyte proliferation and motility, HGF/SF disrupts 
adhesion between melanocytes and keratinocytes by 
downregulating the expression of E-cadherin and 
desmoglein-1, which could favour deregulated cell 
proliferation and invasiveness (60). Interestingly, c-MET is 
a transcriptional target of Mitf, the melanocytic lineage 
transcription factor (68). As described below, the Mitf 
encoding gene (MITF) is amplified in malignant melanoma, 
which might account for c-Met overexpression in advanced 
melanoma. The causal relationship between c-Met 
signaling and malignant melanoma is supported by in vitro 
experiments and genetically engineered models (25).  
 
Other reports have also related overexpression of 
the epidermal growth factor receptor (EGFR), linked to 
gains of chromosome 7, to advanced melanoma (66, 69). 
EGFR is often amplified in breast and lung carcinomas, and 
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overexpression of this tyrosine kinase receptor in tumors is 
thought to result in deregulated kinase activity and 
malignant transformation (70). An important effector of 
oncogenic receptor tyrosine kinases is the 
phosphatydilinositol 3’-kinase (PI3K)-Akt pathway that 
controls cell survival and motility. 
 
4.2. Raf, Ras, and the mitogen-activated protein kinase 
pathway 
  Raf proteins are serine/threonine kinases that are 
the primary mediators of Ras signaling. Ras links 
extracellular mitogenic stimuli to transcription of genes that 
regulate cell growth, differentiation, survival, senescence, 
cell shape and cell migration, via the mitogen-activated 
protein kinase (MAPK) pathway (71) (Figure 4A). In 
humans, there are three highly conserved RAF genes, 
ARAF, BRAF and CRAF, which appear to play distinct 
biological roles. In melanocytic lesions, the most frequent 
activating mutations found in protooncogenes are those 
leading to constitutive activation of the MAPK signaling 
cascade. Strikingly, mutations in BRAF resulting in 
constitutive activation of this kinase have been found 
frequently (27-70%) in melanoma (72-74). Most of these 
BRAF  mutations occur at a single site (T-A transversion) 
leading to the substitution of glutamic acid for valine 
(V600E) at the kinase domain, which confers constitutive 
activation of the MAPK pathway and constitutive nuclear 
factor-kappaB (NF-kappaB) signaling, although it is 
currently unknown how NF-kappaB is activated by 
oncogenic BRAF (75). NF-kappaB regulates the expression 
of a number of chemokines, such as CXCL8, that are thought 
to enhance melanoma progression by autocrine and paracrine 
loops. Thus, overexpression of CXCL8 in melanoma is 
associated with the transition from RGP to VGP melanoma 
and with enhanced angiogenesis (reviewed in ref. 76). BRAF 
mutations are common in benign and dysplastic nevi (72, 77), 
pointing to a potential initiating role of BRAF in melanocyte 
transformation. Expression of mutant BRafV600E protein in 
cultured human melanocytes induces p16Ink4a-dependent cell 
cycle arrest and non-p16Ink4a-dependent cell senescence (78). 
These observations indicate the presence of a tumor suppressor 
within this latter unknown pathway leading to senescence, 
whose inactivation ought to cooperate with BRAF mutations 
for melanoma progression (25). The notion that BRAF 
mutation is not sufficient for a full melanocyte neoplastic 
transformation is also supported by a genetically engineered 
fish model (see below). The BRAFV600E point mutation is not 
classically associated with UV damage, giving rise to the 
question of the role of sun exposure on BRAF mutations 
occurring in melanoma (79). Mutations in BRAF (also 
mutations in N-RAS, see below) are rare in melanomas 
arising in sites exposed to chronic UV damage and in acral 
and mucosal melanomas, but are frequent (about 81%) in 
melanomas occurring as a consequence of episodes of 
acute, high intensity UV exposure, such as the back or 
trunk (80). BRAF mutations are also absent in UV-induced 
non-melanoma skin cancers, such as basal and squamous 
cell carcinomas (81). It has been proposed that BRAF 
mutations in melanoma are not induced directly by UV 
irradiation, but are a secondary consequence of UV 
exposure due to highly toxic oxidazing agents, 
inflammation and erythema (75). 
Other reports have documented RAS gene 
mutations in melanocytic tumors. The most frequently 
mutated member of the family is N-RAS, while mutations in 
H-RAS and K-RAS have only been found occasionally. 
Activating point mutations in N-RAS have been reported in 
as many as 56% of congenital nevi, 33% of primary 
melanomas and 26% of metastatic melanoma samples, but 
are rarely found in dysplastic nevi (82-84). Since BRAF 
mutations, but not N-RAS mutations, are frequent in 
dysplastic nevi, this fact indicates the possible existence of 
two distinct evolutionary pathways of melanoma 
progression, from benign and dysplastic nevi (see Figure 
1), linked to N-RAS and BRAF activation, respectively (10). 
In contrast to BRAF mutations, N-RAS mutations in 
melanoma appear to arise as a result of UV damage (82, 
85). N-RAS and BRAF activating mutations in melanoma 
(as also occur in other tumor types) are mutually exclusive, 
indicating that these genes function in the same cellular 
growth regulatory pathway (80). A recent report (86) has 
found that mutations in BRAF are associated with enhanced 
sensitivity of melanoma cells to pharmacological inhibitors 
of MEK compared to cells harbouring RAS mutations. 
These data suggest that melanoma cells carrying BRAF 
mutations are much more dependent on MAPK signaling 
than RAS mutant cells are, as Ras signaling can diverge 
through other pathways distinc to MAPK. 
 
4.3. PTEN and the phosphatidylinositol 3’-kinase 
pathway 
 PTEN, one of the tumor suppessor genes most 
frequently mutated in cancer, encodes a lipid and protein 
phosphatase involved in negative regulation of the PI3K 
signaling pathway (87). PI3K activation by receptor 
tyrosine kinases (RTKs), G-protein coupled receptors or 
Ras proteins leads to phosphorylation of 
phosphatidylinositol-4, 5-biphosphate (PIP2) to 
phosphatidylinositol-3, 4, 5-triphosphate (PIP3). PIP3 
recruits other proteins to the plasma membrane which lead 
to activation (phosphorylation) of Akt (also known as 
protein kinase B), the major effector of PI3K (Figure 4B). 
Activated Akt phosphorylates several targets, mediating its 
activation or inhibition, resulting in cell growth, survival 
and proliferation. In addition, PI3K has been shown to 
interact with other signaling pathways leading to 
cytoskeletal rearrangements, cell transformation and 
invasion (87). Pten regulates negatively the PI3K pathway 
by dephosphorylation of PIP3 (Figure 4B). Therefore, loss 
or inactivation of Pten leads to constitutive activation of 
PI3K signaling. PTEN germline mutations result in 
Cowden disease, a predisposition syndrome to several types 
of cancer, in which there is not an increased risk for 
melanoma (88). Involvement of PTEN in melanoma was 
suspected because loss-of-heterozygosity (LOH) of 10q 
(where the PTEN locus is located) occurs in 30-50% of 
sporadic melanomas (89). The region deleted at 10q is, 
however, large and could include other tumor suppressor 
genes (39). In addition, somatic mutations in PTEN have 
been found in about 10% of melanomas (90, 91). 
Interestingly, PTEN inactivating mutations in melanoma 
occur in association with activating mutations in BRAF, but 
not N-RAS (92). This is consistent with the fact that Ras 
proteins are able to activate both the PI3K and MAPK 
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Figure 4. (A) The Ras/MAPK signaling pathway. Upon binding of growth factors (GF) to their respective receptor tyrosine 
kinases (RTKs), activation of RTKs stimulates the exchange of GDP for GTP on Ras. The best characterized Ras effector 
pathway proceeds via a kinase cascade involving the sequential phosphorylation of Raf, MEK and Erk. Activated Erks 
translocate into the nucleus where phosphorylate specific transcription factors. (B) The PI3K/Akt signaling pathway. Activation 
of RTKs, or binding of Ras to PI3K, leads to the stabilization of its membrane localization and the activation of its catalytic 
domain which then converts PIP2 into PIP3. PIP3 recruits Akt to the plasma membrane where it can be fully activated by 
phosphorylation by the kinases PDK1 and PDK2. Akt mediates the activation and inhibition of several targets resulting in 
cellular growth, survival and proliferation. In addition PI3K has been shown to regulate the activity of other protein targets 
distinct to Akt. (C) The Wnt/beta-catenin signaling pathway. In the absence of Wnt ligands, free beta-catenin in the cytoplasm is 
rapidly bound to the “destruction complex”, phosphorylated by GSK3beta and degraded through the proteasome. When Wnt 
proteins bind to the G-protein coupled receptor Frizzled, GSK3beta is inhibited and then beta-catenin degradation is reduced. As 
beta-catenin accumulates in the cytoplasm, it enters the nucleus where binds to LEF/TCF transcription factors activating gene 
transcription. LRP, LDL-receptor-related protein; Dsh, Dishevelled; APC, adenomatous polyposis coli; GSK, glycogen synthase 
kinase; TCF, T-cell factor. 
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signaling pathways. Thus, constitutive activation of N-Ras 
in melanoma abrogates the need for specific inactivation of 
Pten. In addition, a recent report has found that promoter 
hypermethylation leading to epigenetic silencing of PTEN 
is another relevant mechanism for loss of this tumor 
suppressor gene in melanoma (93). As a matter of fact, 
expression studies have found the deregulation of the PI3K 
signaling pathway is a common event in melanoma 
development. Thus, increased expression of activated Akt 
(phospho-Akt) was found in dysplastic nevi and metastatic 
melanoma with respect to benign nevi (93, 94). In addition, 
downregulation of Akt, or overexpression of Pten, in 
melanoma cell lines induces apoptosis (95).  
 
4.4. Microphthalmia-associated transcriptional factor  
 Mitf is a transcription factor essential for 
melanocyte cell-fate determination during commitment 
from pluripotent neural crest stem cells (see ref. 96 for a 
review). As mentioned above, Mitf is the major 
transcriptional regulator of pigmentation enzymes, like 
tyrosinase, TRP-1 and DCT (Figure 3B). When mutated in 
mice (Mitfmi/mi mouse) leads to complete absence of neural 
crest-derived melanocytes as well as defects in the retinal 
pigmented epithelium, mast cells and osteoclasts (97). 
These data suggest that Mitf is essential not only for 
differentiation but also for survival of melanocytes. In 
humans, mutations in MITF causes an autosomal inherited 
disease, known as Waardenburg type IIA syndrome, 
characterized by deafness and white hairlock. The 
Waardenburg type IIA syndrome arises from melanocyte 
deficiencies in the eye, forelock and inner ear (98). The 
MITF gene has a complex organization. At least nine 
distinct promoter-exon units direct the synthesis of 
specific Mitf isoforms that originate by alternative 
splicing (99). One isoform, Mitf-M, is specific for the 
melanocyte lineage due to the presence of a unique 
melanocyte-restricted promoter (100). Transcription 
factors that regulate MITF expression include CREB, 
SOX10, TCF/LEF-1 and Mitf itself, among others (96). 
alpha-MSH binds to MC1R which activates adenylate 
cyclase and produces cAMP (Figure 3A). cAMP leads to 
the phosphorylation of CREB transcription factors, 
which in turn activate the MITF promoter. Despite of 
the cAMP-CREB pathway is ubiquitous, MITF 
expression is cell-type specific. This is explained, at 
least in part, by the obligate cooperation between CREB 
and SOX10, which is specific for the neural crest 
lineage (101). TCF/LEF-1 binds beta-catenin at the 
point end of Wingless-type (Wnt) signaling (Figure 4C) 
linking MITF with the Wnt/beta-catenin signaling 
pathway, which is crucial for the differentiation of 
melanocytes from the neural crest (102-104). In 
addition, Mitf is regulated by post-translational 
mechanisms, namely by phosphorylation (Figure 3A). 
Nevertheless, the role of phosphorylation on Mitf 
activity is obscure. For example, phosphorylation of 
Mitf by Erk2 increases recruitment of the transcriptional 
coactivator p300/CBP, a CREB binding protein, and 
enhances MITF transcriptional activity, while 
simultaneously targets Mitf for ubiquitin-dependent 
proteolysis (105, 106).  
 Genomic amplification of MITF has been found 
in 10-20% of primary melanomas with a higher incidence 
in metastatic melanoma (107). Strong MITF gene 
amplification correlates with a reduced disease-specific 
patient survival and, therefore, MITF amplification seems 
to be a useful prognostic marker for metastatic melanoma 
(107, 108). In addition, functional studies on immortalized 
melanocytes that have inactivated the p53 and pRb 
pathways showed that ectopic overexpression of Mitf 
complemented BRafV600E to confer soft-agar clonogenic 
growth, suggesting that MITF is an oncogene in human 
melanoma, particularly in the setting of cell cycle 
deregulation and excess of MAPK signaling activation 
(107). In this study, MITF amplification was also 
associated with resistance to chemotherapy (107). 
However, this fact could not be confirmed in a subsequent 
report (108). Remarkably, other authors have found that the 
expression of MITF and its targets (Tyrosinase, TRP-1 and 
DCT) are downregulated in advanced melanoma (109). 
Moreover, upon transformation of murine melanocytes by 
oncogenic BRAF, Mitf expression is downregulated, and 
reexpression of Mitf inhibits proliferation of transformed 
melanocytes (110). These observations support a Janus-
faced role for Mitf on the development of melanoma (108), 
and suggest that there are distinct subsets of melanoma 
tumors. In some melanomas, cell survival is dependent on 
Mitf (106), while in others decreased expression of Mitf 
might provide a growth advantage by diminishing energy 
and oxidative stress associated with pigment production 
(96). 
 
4.5. The Wnt/beta-catenin signalling pathway 
 In the human epidermis, melanocytes establish 
close contacts with the neighboring keratinocytes that are 
mediated by the cell-cell adhesion protein E-cadherin (66). 
In the adhesion complex, beta-catenin interacts with E-
cadherin and alpha-catenin, this latter also binds to the actin 
cytoskeleton (Figure 4C). In epithelial cells, any beta-
catenin free in the cytoplasm (not bound to E-cadherin) is 
immediately ubiquitinated and degraded by the proteasome. 
Beta-catenin degradation involves the formation of a 
multiprotein complex with the adenomatous poliposis coli 
(APC) protein, axin and glycogen synthase kinase 
(GSK3beta). GSK3beta phosphorylates beta-catenin in 
serine/threonine leading to its ubiquitination and 
proteolysis (111). In colon cancer, inherited and somatic 
mutations in the tumor suppressor APC reduce the 
degradation of beta-catenin and cause its accumulation into 
the nucleus, where it interacts with DNA-bound TCF and 
LEF family members of transcription factors to activate the 
expression of target genes. Similarly, both gain-of-function 
mutations in phosphorylation residues of beta-catenin 
(encoded by the locus CTNNB1) and loss-of-function 
mutations in axin activate beta-catenin signaling and are 
linked to cancer (see ref. 112 for a review).  
 
 Wnts are secreted cystein-rich glycoproteins, 
from which at least 19 members are known in humans. 
These factors bind to target cells via two families of 
receptors: the Frizzled family of serpentine receptors and 
LDL-receptor-related proteins (LRP) 5 and 6. Wnt proteins 
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activate at least three different intracellular signaling 
pathways: the canonical Wnt/beta-catenin pathway, 
Wnt/Ca2+ and Wnt/planar polarity (112). Beta-catenin 
signaling is activated in response to the formation of a 
complex containing Wnt, Frizzled and LRP. LRP receptor 
is then serine-phosphorylated by an unknown kinase 
allowing to the recruitment of axin to the plasma membrane 
and the activation and membrane recruitment of the 
phosphoprotein Dishevelled (Dsh). Dsh appears to interact 
with axin as well as with the “destruction complex” for 
beta-catenin leading to axin degradation and inhibition of 
GSK3beta (Figure 4C). As beta-catenin levels rise, it 
accumulates in the nucleus where, as mentioned above, in 
association with TCF/LEF proteins, activates the 
transcription of about 412 target genes.  
 
 The Wnt/beta-catenin signaling pathway is 
involved in melanocytic lineage commitment decisions of 
neural crest cell derivatives (113).  Mitf is a 
developmentally Wnt/beta-catenin target gene (102), and 
several studies have reported upregulation of Mitf by 
Wnt/beta-catenin in melanocyte and melanoma cells (103, 
104). A hallmark of the activation of this pathway in 
melanoma is the immunohistochemical observation of 
nuclear beta-catenin localization in about 30% of human 
melanomas (114), suggesting that constitutive activation of 
Wnt/beta-catenin signaling is a frequent event in melanoma 
(see ref. 115 for a review). However, although a relatively 
high incidence of stabilizing beta-catenin mutations have 
been observed in melanoma cell lines (116), mutations in 
beta-catenin and in other components of the pathway, such 
as APC, are infrequent in primary melanomas (114, 117, 
118). Therefore, at present, the molecular mechanisms 
involved in the deregulation of this pathway in melanocytic 
lesions are obscure. 
 
5. GENETICALLY ENGINEERED ANIMAL 
MODELS OF MELANOMA 
 
Most of the genes found to be mutated (or 
altered) in melanoma have been tested in animal models, 
particularly in mice. Thus, a large number of genetically 
engineered mouse models have been generated in different 
laboratories (reviewed in refs. 25, 96 and 119), the most 
significant of which are summarized in Table 1. These 
mouse models have permitted to assess the requirement of 
genetic interactions between distinct pathways, as well as 
interactions of those pathways with the environment, in 
order to recapitulate human melanoma disease. 
Nevertheless, while most melanocytes in human skin are 
found at the epidermal basal layer and within hair follicles, 
mouse epidermal melanocytes are mostly located in hair 
follicles and rarely found in the interfollicular epidermis. 
Therefore, mouse and human skin are not identical and, 
thus, caution should be taken in order to extrapolate the 
observations made in mouse models to human melanoma.   
 
The first successful melanoma mouse model was 
developed by targeted expression of simian virus 40 
(SV40) large tumor (T)-antigen (Ag) to melanocytes under 
the control of the Tyrosinase promoter (120). The T-
antigen interacts with host proteins inactivating pRb and 
p53 functions in a manner reminiscent of p16Ink4a and 
p19Arf loss. Tyr-SV40 T-Ag+ transgenic mice produced 
skin melanomas at low frequency that appeared late on life, 
although developed metastatic skin melanoma when 
exposed to limited UVB radiation shortly after birth (121, 
122). In contrast, these transgenic mice produced highly 
aggressive ocular melanomas that originated spontaneously 
at a young age (120).  
 
Mice knock-out for p16Ink4a that retain p19Arf 
are predisposed to develop melanoma after initiation with 
the chemical carcinogen 7, 12-dimethylbenz(a)anthracene 
(DMBA) (123). Moreover, treatment with DMBA of 
p16Ink4a-deficient mice that were heterozygous for p19Arf 
resulted in increased incidence of cutaneous melanoma that 
produced frequent metastasis (124). These studies have 
provided compelling evidence that inactivation of both the 
pRb and p19Arf/p53 pathways are crucial for development 
of melanoma. The cooperation between these two pathways 
and that of PI3K-Akt has been evaluated in compound 
mutant p16Ink4a/p19Arf-deficient mice heterozygous for 
Pten. These mice spontaneously developed a wide 
spectrum of tumor types including melanoma (125). 
DMBA was also able to enhance melanomagenesis in mice 
harbouring a Cdk4 mutation that inactivates the pRb 
pathway, as found in familial melanoma (40, 126). 
 
A large number of Ras transgenic mouse models for 
melanoma have been developed in the past years, most of 
which express an activated form of the H-Ras gene. Adult 
transgenic mice expressing an H-RasV12G oncogene in 
melanocytes have been chronically exposed to either UVB 
irradiation or DMBA. Both challenges produced 
melanoma, but at low efficiency (127). Of note, DMBA, a 
chemical agent of unknown environmental relevance for 
human melanoma, was most efficient than UV to induce 
melanoma in this and other mouse models (see Table 1). 
Loss of either p16Ink4a or p19Arf (or Trp53 encoding p53) 
in Tyr-H-RasV12G+ transgenic mice induced spontaneous 
skin melanomas with high incidence (128, 129).  The 
cooperation between UV irradiation and the loss of each 
Cdkn2a encoding tumor suppressor gene was also 
examined in H-Ras+ transgenic mice (130). The results of 
these studies show that loss of p19Arf, but not of p16Ink4a, 
cooperates with UVB exposure to accelerate melanoma 
development. Tumors arising in UVB-irradiated H-Ras+/ 
p19Arf-/- mice showed either loss of p16Ink4a or Cdk6 
amplifications (both leading to disruption of the pRb 
pathway), these data indicate a joint cooperation between 
mutations at both p53 and pRb pathways and UV 
irradiation for UV-induced melanomagenesis. An 
additional mouse melanoma model null for the Cdnk2a 
locus in which the H-RasV12G oncogene is expressed in a 
doxycycline-inducible manner showed that H-Ras 
activation was essential not only for melanomagenesis but 
also for melanoma maintenance (131). However, the H-
Ras+ transgenic mouse models have some limitations to 
emulate the human disease, as tumors are non-pigmented 
and no metastasis is found in these animals (Table 1). Since 
H-RAS mutations are rare in human melanoma compared 
with N-RAS mutations (see above), it was extremely 
valuable the generation of a transgenic mouse model
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Table 1. Genetically engineered melanoma mouse models 
Transgene Knock-out Carcinogen 
exposure 
Tumor phenotype/Comments Reference 
- Hypopigmentation; low penetrance skin melanoma; metastatic eye 
melanoma. 
120  
Tyr-SV40 T-Ag+ 
 
 
- 
 
UV 
 
Short term, neonatal, UVB exposure induced melanocytic skin lesions 
and metastatic melanoma. 
121, 122 
 
p16Ink4a -/- DMBA Low penetrance skin melanoma. 123 
p16Ink4a-/-, p19Arf +/- DMBA Metastatic skin melanoma. 124 
 
 
      - p16Ink4a-/-,p19Arf-/-, Pten +/- - Low penetrance skin melanoma. 125 
- Low penetrance skin melanoma. 126  
Cdk4 (R24C)+ 
- 
DMBA/TP
A 
High penetrance skin melanoma, no metastasis. 40 
- Low penetrance metastatic skin melanoma 133, 134  
- UV Single, neonatal, UVB exposure (but not UVA exposure) enhanced 
melanomagenesis; chronic adult UVB exposure had no effect. 
135-137 
p16Ink4a -/- UV Single neonatal UVB exposure induced skin melanoma (mean onset age 
of ~ 7 months). 
56 
p19Arf -/- UV Single neonatal UVB exposure induced skin melanoma (mean onset age 
of ~ 3.5. months). 
56 
p16Ink4a-/-, p19Arf -/- UV Both loss of p16Ink4a/p19Arf function and single, neonatal, UV 
exposure enhanced melanomagenesis. 
138 
 
 
 
 
MT-HGF/SF+ 
 
Trp53 -/- UV Single neonatal UVB exposure did not induce melanocytic lesions. 56 
- DMBA/UV 
 
No spontaneous skin tumors without carcinogen; each carcinogen 
induced melanoma; DMBA was superior to chronic adult UVB 
exposure. 
127 
- High penetrance, nonmetastatic skin melanoma. 128, 129 p16Ink4a -/- 
UV 
 
Single, neonatal, UVB exposure had no impact in melanoma 
development. 
130 
- High penetrance, nonmetastatic skin melanoma. 128, 129 p19Arf -/- 
UV 
 
Single, neonatal, UVB exposure accelerated melanomagenesis. 130 
 
 
 
Tyr-HRasV12G+ 
Trp53 -/- - High penetrance, nonmetastatic skin melanoma. 128, 129 
- - Hyperpigmentation, low penetrance, metastatic skin melanoma. 132 Tyr-NRasQ16K+ 
p16Ink4a-/-, p19Arf -/- - High penetrance, metastatic skin melanoma. 132 
DMBA: 7, 12-dimethylbenzanthracene; TPA: 12-O-tetradecanoylphorbol-13-acetate 
 
expressing an activated N-RasQ61K oncogene (132). The 
Tyr-N-RasQ61K+ transgenic mice had hyperpigmented skin 
and developed cutaneous metastasizing melanomas. 
Moreover, on a p16Ink4a/p19Arf-deficient background, 
these transgenic mice had accelerated melanomagenesis 
and developed metastatic melanoma with high penetrance 
(132).  
 
Interactions between receptor tyrosine kinase 
signaling and UV irradiation have been investigated in the 
MT-HGF/SF+ transgenic mouse model in which the 
cytokine HGF/SF is expressed under the control of the 
ubiquitous metallothienin-1 (MT) promoter. These mice 
develop melanomas, but after long latency periods (133, 
134), suggesting that additional genetic alterations are 
needed for melanoma development. A single neonatal dose 
of UVB radiation was sufficient to induce melanoma 
lesions with high penetrance and short latencies in MT-
HGF/SF+ transgenic mice, while chronic UVB exposure in 
adult mice had no effect (135, 136). This model was also 
useful to demonstrate that it is the UVB portion of the 
sunlight spectrum and not UVA responsible for initiation of 
melanoma (137). The response of these mice is in 
accordance with epidemiological studies in humans 
suggesting that melanoma is caused by intense intermittent 
exposure to UVB during childhood, rather than cumulative 
sun exposure during adulthood, as mentioned above (2, 4). 
The cooperation between neonatal UVB irradiation and 
inactivation of the Cdnk2a locus has been further 
demonstrated in HGF/SF+ transgenic mice. UVB-irradiated 
HGF/SF+/ p16Ink4a-/-/p19Arf-/- mice exhibited a significant 
acceleration of melanoma development with respect to 
untreated mice and UVB-irradiated HGF/SF+ mice with an 
intact Cdkn2a locus (138).  Interestingly,  HGF/SF+ 
transgenic mice in which either one or both Trp53 alleles 
were inactivated failed to develop melanocytic lesions after 
neonatal UVB irradiation. In contrast, HGF/SF+ mice 
deficient for p19Arf developed melanoma with a mean 
onset age of about 3.5. months (57). These data suggest that 
although p19Arf and p53 proteins are linked in a common 
pathway, it is the loss of p19Arf function which is critical 
for the development of melanoma. Moreover, experiments 
with cultured cells showed that unlike fibroblasts, where 
p19Arf can only trigger cell growth arrest and senescence 
in the presence of a functional p53, p19Arf regulate 
melanocyte senescence in a p53-independent manner (57).   
 
Melanoma genetic models also include animals 
distinct from the mouse, such as zebrafish and Xiphophorus 
fish. Thus, while there has been no report to date on a BRaf 
transgenic mouse model for melanoma, it has been shown 
that activating mutations of BRaf in zebrafish, which leads 
only to development of benign nevi, cooperate with 
inactivation of p53 for melanoma development (139). In 
Xiphophorus fish, activating mutations in Xmrk, the EGFR 
homolog, enhances melanoma susceptibility (140, 141). 
This observation is interesting, as no activating mutations 
in EGFR have been found in human melanoma. However, 
it is in agreement with a number of studies on melanoma 
cell lines demonstrating that sustained activation of the 
EGFR signaling pathway provides potent autocrine survival 
signals for RAS-driven melanoma tumorigenicity (25).  
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6. GENOMIC AND GENE EXPRESSION 
PROFILING STUDIES 
  
As described in the Introduction section, it is 
clear that melanoma is a heterogeneous clinical and 
histopathological entity. Recent studies using genomic 
high-throughput screening techniques have shed new light 
on the molecular events associated with the heterogeneity 
of melanoma (142-146). These techniques that enable the 
analysis of the expression of multiple genes in large series 
of tumor samples have begun to build a new molecular 
classification strategy of melanoma and have led to the 
identification of novel genes associated with melanoma 
progression. In this section, we review the results of 
expression studies using cDNA or tissue array 
technologies, as well as those from accurate quantification 
of DNA copy number variation by using comparative 
genomic hybridization (CGH). 
 
6.1. Gene expression profiles 
 Most of gene expression analyses on melanoma 
have been performed on cell lines. Some studies used cell 
lines with different aggressiveness or metastatic behaviour 
(147, 148), while others attempted to define gene profiles 
that are regulated by oncogenic BRAF or N-RAS, or 
induced by UVA or UVB radiation, or even related to the 
different sensitivity of cell lines to the treatment with 
interferons (reviewed in refs. 75, 142 and 149). The results 
of these studies failed to fulfil the expectations in order to 
identify a molecular signature for melanoma metastasis or 
to discover potential targets for new therapeutic options, 
but they represented a stimulus for further analyses, 
strikingly on primary melanomas. A recent report on 
primary melanomas (150) showed that the gene profile of a 
subgroup of metastatic melanomas matched that of RGP 
melanoma, suggesting the possibility that melanoma can 
metastasize even in the radial phase of growth. Molecular 
signatures of invasive cutaneous (151) and uveal (152) 
melanoma have also been reported. More recently, some 
reports used large-scale gene expression profiling analyses 
on primary human melanomas from patients with long 
clinical follow-up (153-155). However, in these studies, 
comparison was limited almost exclusively to VGP 
melanoma and metastatic melanoma and, therefore, the 
genes identified may be associated with the latest stage of 
melanoma progression. Overall, the results of these gene 
expression analyses suggest that progression to metastatic 
melanoma implies dysregulation of clusters of genes 
involved in cell cycle, apoptosis, immune response, 
metabolism, signal transduction, transcriptional regulation, 
protein synthesis and degradation, remodelling of the 
extracellular matrix and epithelial-mesenchymal transition 
(EMT). We summarize the most important results of these 
analyses in Table 2.  
 
The panel of genes presented in Table 2 include 
products related to cell cycle regulation, mitosis and DNA 
replication, such as the proliferation cell nuclear antigen 
(PCNA), cell division cycle 6 (Cdc6) and Cdc28/Cdk1 
protein kinase regulatory subunit 2, all of them 
overexpressed in metastatic melanoma and linked to poor 
prognosis (153, 155). Particularly interesting is the finding 
that high levels of geminin and minichromosome 
maintenance (MCM) proteins are associated with high risk 
of melanoma metastasis and death (153).  These proteins 
are involved in the control of DNA replication and genomic 
stability during cell cycling. Geminin controls that genomic 
DNA is fully replicated only once during each cell division 
by inhibiting the replication licensing factor Cdt1, thus 
avoiding that MDM proteins, which unwind DNA at 
replication origins, are further recruited to these sites (156). 
Other cell cycle-related products upregulated during 
melanoma progression are the subunit gamma of the 
eukaryotic translation initiation factor 2 (eIF2gamma) and 
the ubiquitin conjugation enzyme E2I (UBE2I), this latter 
involved in the ubiquitination and degradation pathway of 
cell cycle regulatory proteins. eIF2gamma seems to be 
transiently upregulated in melanomas with respect to nevi 
and metastasis and may contribute to develop autonomous 
melanoma growth, while  UBE2I is progressively 
upregulated in melanomas and metastases in comparison 
with nevi (157). A recent report from the same laboratory 
has found upregulation of the ataxia telangiectasia-mutated 
(ATM) protein kinase in nodular malignant (VGP) 
melanoma and deep penetrating nevi, a variant of benign 
melanocytic nevus with clinical and histological features 
mimicking VGP melanoma (158). ATM plays a central role 
in the DNA damage response and is involved in cell cycle 
control and DNA repair (159). In addition, a number of 
pro-apoptotic genes, including the member of the forkhead 
box gene family FOXQ1, the gene encoding tumor protein 
p73-like (TPL73L) as well as members of the tumor 
necrosis factor (TNF) receptor superfamily and ligands 
have been found to be downregulated during the transition 
from non-invasive RGP melanoma to the potentially 
metastatic VGP melanoma (160). The same occurs with 
members of the caspase and calpain families, indicating an 
important role for loss of apoptotic mechanisms in 
melanoma progression (160).  
 
 Several reports point to a significant group of 
genes dysregulated in invasive melanoma which are 
involved in EMT. EMT is the process by which epithelial 
cells lose their polarity, loose cell-cell contacts with 
neighbouring cells, reorganize their cytoskeleton and 
express mesenchymal markers. Consequently, these tumor 
cells become motile and interact with the extracellular 
matrix, invading surrounding tissues and acquiring the 
capacity to metastasize (161). Although melanoma cells are 
not epithelial in nature, these EMT genes (that were 
previously identified as a determinant of local invasion and 
metastasis in carcinomas) also appear to be relevant for 
malignant melanoma. For instance, the cadherin switch by 
which loss of epithelial E-cadherin is associated with gain 
of neural N-cadherin during progression to metastatic 
melanoma (154, 155, 162) is supported by experimental 
approaches with melanoma cell lines (163-165). Increased 
N-cadherin expression in VGP melanoma favours cell-cell 
contacts of melanoma with stromal cells and enhances 
survival of melanoma cells by stimulating beta-catenin 
signaling (166). Overexpression of N-cadherin in 
metastatic VGP melanoma also matches with 
downregulation of cadherin 10, a type II cadherin with
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Table 2. Gene expression signatures in melanoma tumor progression 
Accession 
number 
Gene name Protein Function Expression Commentary Reference 
 Cell cycle-
related genes 
     
NM_001415 EIF2 gamma EIF2 subunit gamma DNA translation Up Tumour progression 157 
NM_003345 UBE2I Ubiquitin-conjugating 
enzyme E2I 
Ubiquitine pathway, G1/S 
control 
Up Tumour progression 157 
NM_015895 GMNN Geminin DNA replication inhibitor  Up High risk of metastasis  153 
NM_002592 PCNA PCNA Cofactor DNA polymerase Up Genome destabilization 153 
NM_002388 
NM_005914 
NM_005915 
MCM3, 4, 6 MCM components 3, 4, 6 DNA replication Up High risk of metastasis 153 
NM_001254 CDC6 CdC6 Cell cycle control Up Poor prognosis 155 
NM_001827 CKS2 Cdc28/Cdk1 protein kinase 
subunit 2 
Cell cycle control Up Poor prognosis 155 
 
NM_000051 
 
ATM 
 
ATM kinase 
DNA damage response. 
Cell cycle control 
 
Up 
Associated with 
melanocytic infiltration 
 
158 
 
 EMT-related 
genes 
     
NM_004360 CDH1 E-cadherin Cell-cell adhesion Down Tumour progression 154, 155, 
162 
NM_001793 CDH3 P-cadherin Cell-cell adhesion Down Tumor progression 150, 162 
NM_006727 CDH10 Cadherin-10 Cell-cell adhesion Down High risk of metastasis 154 
NM_001792 CDH2 N-cadherin Cell-cell adhesion Up Melanoma invasiveness  154, 162 
NM_001795 CDH5 VE-cadherin Cell-cell adhesion Up Tumor progression 167 
NM_004431 EPHA2 Ephrin receptor EphA2 Cell signaling Up Tumour progression 154, 168 
NM_002421 
NM_004530 
MMP-1, -2 Matrix metalloproteinases 1 
and 2 
Degradation of the 
extracellular matrix 
Up Tumour progression 169 
NM_000582 SPP1 Osteopontin MMP`s inductor  Up High risk of metastasis 154, 155 
NM_003118 SPARC  Osteonectin Angiogenesis  Up Tumour progression 154 
NM_003392 WNT5A  Wnt5a Cell signalling Up Melanoma invasiveness  151, 171 
NM_004948 DSC1  Desmocollin 1 Desmosomal component  Down Loss off cell adhesion 155 
 Others genes      
NM_001922 DCT Dopachrome tautomerase Melanin synthesis Up Tumour progression 157 
NM_000245 HGFR (c-MET) HGF/SF receptor  Cell signaling Up Tumor progression 172 
NM_002266 KPNA2 karyopherin alpha 2 Nuclear import of proteins Up Poor prognosis 153 
 
similar binding strength than E-cadherin (154). Moreover, 
P-cadherin, another important cell-cell adhesion receptor 
for the interaction of melanocytes with keratinocytes, was 
also found to be downregulated or lost in malignant 
melanoma (150, 162). Conversely, microarray analyses on 
cell lines revealed that the typical cell-cell adhesion 
receptor for endothelial cells, VE-cadherin, is dramatically 
overexpressed in aggressive cutaneous and uveal melanoma 
cells (167-169). The finding that VE-cadherin is 
overexpressed in malignant melanoma cells together with 
other key molecules involved in the formation of 
vasculogenic-like networks, such as EphA2 and laminin 
5gamma2  (168) allowed Hendrix and colleagues to 
introduce the term of “vasculogenic mimicry”. EphA2 is a 
member of the ephrin tyrosine kinase family of receptors 
while laminin 5gamma2  is a component of the 
extracellular matrix (169). The concept “vasculogenic 
mimicry” describes the plasticity and unique ability of 
aggressive melanoma cells to form tubular structures and 
patterned networks in three-dimensional cultures that 
mimic embryonic vasculogenic networks (170). 
Osteopontin, a secreted phosphoprotein that promotes 
antiapoptotic signals as well as angiogenesis, and the 
expression of matrix metalloproteinases (MMPs) and 
osteonectin (SPARC), a secreted extracellular matrix 
protein involved in tumor cell migration, invasion and 
angiogenesis, were also found to be upregulated in 
aggressive melanomas (154, 155). These proteins are 
associated with melanoma cell migration/invasion by 
inducing specific interactions between tumor and stromal
 
cells and contributing to remodel the extracellular matrix. 
The collagenases MMP-1 and MMP-2 are overexpressed in 
aggressive with respect  to poorly aggressive melanoma 
cell lines (169), and MMP-2 and ADAM9 (disintegrin and 
metalloproteinase domain 9) were found to be upregulated 
in metastatic VGP melanoma (154). Remarkably, Wnt5a, a 
member of the Wnt family of secreted factors, has also 
been associated with melanoma cell migration and 
invasion. The Wnt5a protein signals via a non-canonical 
Wnt pathway to activate phospholipase C, causing 
phospholipids turnover in the membrane, releasing calcium 
from intracellular stores and increasing the activity of PKC 
(112). Overexpression of Wnt5a has been found in 
melanoma tumors and cell lines associated with increased 
motility and invasiveness and poor clinical outcome (151, 
171). It is thought that Wnt5a contributes to melanoma 
progression through its activation of PKC (171). 
 
 Microarray technology was also useful to confirm 
that the MAPK pathway is activated in metastatic 
melanoma, as the HGF/SF receptor (c-Met) and other 
components of the HGF/SF-activated MAPK pathway were 
significantly upregulated in melanoma metastases and 
melanoma cell lines compared with normal melanocytes 
(172). 
 
6.2. Comparative genomic hybridization    
 High-resolution genomic techniques to scan 
extensive chromosomal rearrangements are providing 
valuable results in melanoma. This type of integrated
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Table 3. Summary of chromosomal alterations involving known genes found in melanoma 
Chromosomal aberrations Gene candidate Protein Commentary Reference 
Gains/amplifications     
3p14 MITF Mitf Cutaneous malignant 
melanomas 
107, 173 
7q21.3.-qter BRAF Braf  Cutaneous melanomas 64, 173 
8q23-qter c-MYC c-Myc-1 Primary and metastatic 
cutaneous and ocular 
melanomas 
64, 174-176 
11p HRAS  H-Ras  Spitz nevi 177, 178 
11q13 CCND1 cyclin D1 Acral and mucosal 
melanomas 
80 
12q14 CDK4  Cdk4 Acral and mucosal 
melanomas 
80 
18q CDH2 N-cadherin Metastatic cutaneous and 
uveal melanomas 
174, 179 
 
Losses     
1p31 ITGB3BP  beta 3 endonexin  Uveal melanomas 180 
9p CDKN2A  p16Ink4a/ p14Arf Primary and metastatic 
melanomas 
64, 80 
10q PTEN Pten Primary and metastatic 
melanomas 
64, 80, 174 
 
genomic approach led to the identification of MITF as an 
oncogene amplified in melanoma (107, 173). Also, Curtin 
and co-workers afforded the first consistent molecular 
classification of melanoma by comparing genome-wide 
alterations in the number of copies of DNA and mutational 
status of BRAF and N-RAS in melanomas differing in the 
degree of UV light exposure (80). This latter study 
provided the definitive proof that melanoma is a genetically 
heterogeneous disease (144). Acral (palms and soles) and 
mucosal melanomas exhibited higher genetic instability, 
with abundant chromosomal gains and losses, 
intrachromosomal copy number changes and focal 
amplifications, than melanomas arising on skin with 
chronic or intermittent sun exposure. In addition, the 
mutational spectrum in N-RAS and BRAF was different 
between melanomas from sun-exposed and sun-protected 
skin (see above). Gains/amplification of CCND1, the gene 
located on chromosome 11q13 that encodes cyclin D1, 
inversely correlated with mutations in BRAF independently 
of the type of melanoma. Amplifications of CDK4 (located 
on chromosome 12q14), which encodes a cyclin D1 
binding partner, were more common in acral and mucosal 
melanomas than in melanomas arising in sun-exposed skin, 
and did not were observed in tumors with mutations in 
either BRAF or N-RAS, or in tumors which had 
amplification of CCND1 (80). Interestingly, the most 
commonly lost genomic region in melanomas is 9p 
containing the CDKN2A locus (64, 80). In the study by 
Curtin and co-workers, losses of CDKN2A were more 
common in acral and mucosal melanomas, and 
homozygous deletions of CDKN2A occurred exclusively in 
tumors without CDK4 amplifications. In a former study by 
Bastian and colleagues, losses of chromosomes 9 and 10 
occurred early on in melanoma progression (RGP 
melanoma), whereas gains of chromosome 7 containing 
BRAF occurred later (64). Loss of chromosome 10 
containing the PTEN tumor suppressor gene is another 
frequent genetic alteration found in acral and mucosal 
melanomas as well as in melanomas arising as a 
consequence of intermittent sun exposure, and correlates 
positively with mutations in BRAF (80). These data are 
consistent with observations made by other laboratories 
(see above). Table 3 summarizes the most significant
 
chromosomal alterations found in melanoma that involve 
well known candidate genes. Overrepresentation of 8q23-
qter harbouring c-MYC and amplification of this oncogene 
by fluorescence in situ hybridization (FISH) have been 
detected in primary and metastatic cutaneous melanoma 
(174). Interestingly, gain of this region is the most frequent 
genetic change found in uveal (ciliary body and chroid) and 
ocular melanoma (175, 176). According to a recent study, 
the most powerful predictor of poor prognosis in uveal 
melanoma is gain of 18q11.2 (179). Gains of 18q were also 
found in cutaneous melanoma associated with metastasis 
(174). Interestingly, the 18q11.2 region harbors the N-
cadherin gene which, as already mentioned, is 
overexpressed in cutaneous VGP and metastatic melanoma. 
Another common genetic alteration detected in uveal 
melanoma is LOH of 1p31 harboring the gene encoding 
beta3-endonexin, which binds to the cytoplasmic tail of 
beta3 integrins and modulates integrin function (180). 
Gains of 11p have been found in a subset of Spitz nevi or 
“juvenile melanoma”, a benign melanocytic tumor typical 
of childhood with histopathological characteristics of 
melanoma that usually have a normal chromosomal 
complement at the level of CGH (177). A candidate 
oncogene on 11p is H-RAS, as the majority of Spitz nevi 
with increased copy number of chromosome 11p show 
activating mutations in the H-RAS locus (178). As these 
and other reported genomic alterations occurring in 
melanoma contain large chromosomal regions, much work 
is needed in order to identify other candidate genes whose 
implication in melanoma can be validated by functional 
experimental strategies. 
 
7. MELANOMA STEM CELLS  
 
 Stem cells are self-renewal cells that have the 
ability to differentiate into various cell lineages. Stem cells 
are located in restrictive environments, called niches, and 
interactions between stem cells and their microenvironment 
are crucial to the self-renewal process. Stem cells, though 
highly clonogenic, are relatively quiescent or slow cycling 
in response to survival and proliferation stimuli. Due to this 
infrequently dividing nature, stem cells are characterized as 
label-retaining cells when incorporate DNA synthesis 
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labels such as tritiated thymidine or bromodeoxyuridine 
(181). Stem cells divide asymmetrically giving rise to one 
daughter cell that remains as a stem cell (self-renewal) and 
another daughter cell that rapidly divides and differentiate. 
Melanocytes found in the skin and in the choroid layer of 
the eye derive from the neural crest, a transitory structure 
formed at the dorsal borders of the neural plate during 
development of vertebrates. Neural crest cells undergo an 
EMT to migrate along definite pathways in the embryo. 
They stop at different locations to give rise to a large array 
of differentiated cells including peripheral neurons and glia, 
endocrine and cartilage cells and melanocytes (182). 
Melanocytic precursors, melanoblasts (unpigmented cells 
with the potential to produce melanin) invade all skin areas 
and differentiate into melanocytes. How neural crest cells 
become committed to the melanocytic lineage and which 
are the factors controlling survival, proliferation and 
differentiation of melanocyte precursors are still not 
completely clear. The analysis of mouse white spotting 
mutants allowed to the identification of stem cell factor 
(SCF, also denominated as steel factor) and its tyrosine 
kinase receptor c-Kit as crucial components of a pathway 
required for survival and migration of pigment precursors 
(183). Other studies characterized the implication of 
endothelins, a family of vasoactive peptides that bind to G-
protein-coupled receptors (184), in the development of 
subsets of neural crest-derived cell types, including 
melanocytes. In particular, endothelin-3 appears to be 
required together with SCF/c-Kit for migration of early 
melanoblasts in the dermis (reviewed in ref. 182). c-Kit 
signaling is known to regulate Mitf activity via the MAPK 
pathway (185). As aforementioned, Mitf is a key 
transcription factor for melanocyte development and 
survival. Another pathway likely involved in melanocytic 
development is Wnt/beta-catenin that controls neural crest 
cell fate and also activates Mitf expression (102, 113). In 
fact, Fang and colleagues (186), using a combination of 
Wnt3a, endothelin-3 and SCF, were able to derive 
melanocytes from human embryonic stem cells. These 
melanocytes were able to migrate to the epidermal basal 
layer in reconstituted skin.  
 
A population that fulfils the criteria for 
melanocyte stem cells was identified by Nishimura and co-
workers in the lower permanent portion of mouse hair 
follicles (187). However, it is unknown whether this cell 
population is multipotent or restricted to the melanocytic 
lineage. Interestingly, a population of multipotent adult 
stem cells, that gives rise to differentiated smooth muscle 
cells, neurons and melanocytes, has been isolated from 
human hair follicles (188). Notch signaling was 
demonstrated to exert a key role in the survival of murine 
melanocyte stem cells and embryonic melanoblasts, likely 
by inhibiting apoptosis (189, 190). Notch regulates an 
enormous diversity of developmental processes and its 
dysfunction is implicated in many cancers (191). In 
melanoma, constitutive activation of the Notch pathway has 
been involved in both the early transformation of 
melanocytes into melanoma and in the acquisition of the 
metastatic phenotype (reviewed in ref. 190). The oncogenic 
effect of Notch in melanoma appears to be mediated by 
activation of beta-catenin signaling (192), although 
constitutive Notch activation also regulates MAPK and 
PI3K/Akt pathways in human melanoma cells (190). 
Inhibitors of Notch induce apoptosis in melanoma cell 
lines, but not in normal melanocytes (193). It has been 
suggested this fact as indicative of the existence of a 
melanoma stem cell population, since Notch appears to be 
required for the maintenance and survival of melanocyte 
stem cells (190). 
 
The cancer stem cell theory suggests that cancer 
originates from a minor subpopulation of neoplastic stem 
cells that hold the potential of self-renewal and are entirely 
responsible for sustaining the tumor and for giving rise to 
proliferating but progressively differentiating cells that 
contribute to the cellular heterogeneity of the tumor (194). 
Cancer stem cells may arise from adult undifferentiated 
stem cells or from differentiated cells that have acquired 
stem cell characteristics. A large body of evidence suggests 
that aggressive melanoma cells acquire, like embryonic 
stem cells, a multipotent, plastic phenotype (195). Bittner 
and colleagues were the first to show that aggressive 
melanoma cells express genes associated with different cell 
types, including those of endothelial, epithelial, 
fibroblastic, hematopoietic, neuronal and progenitor cells 
(151). Moreover, melanocytic-specific genes are 
downregulated in metastatic melanomas. Thus, 
pigmentation-related genes, such as MLANA (melan-A) and 
Tyrosinase are dramatically reduced in aggressive 
melanomas with respect to their poorly aggressive 
counterparts (195). A nice example of melanoma plasticity 
is the aforementioned “vasculogenic mimicry” by which 
aggressive melanoma cells express endothelial-associated 
genes and form extravascular fluid-conducting networks 
that allow them to adapt to the hypoxic microenvironment 
of rapidly growing tumors (170, 195). Cells with stem cell-
like features, such as the ability to grow as nonadherent cell 
aggregates (called spheres or spheroids), have been isolated 
from different melanoma cell lines (196). Spheroid cells 
were able to self-renew and differentiate into melanogenic, 
adipogenic, chondrogenic, and osteogenic lineages. A 
subset of spheroid cells expressed the cell surface marker 
CD20, a product identified by gene expression profiling 
studies as part of the molecular signature of aggressive 
melanomas (151). CD20 is a standard therapeutic target for 
treatment of non-Hodkin’s lymphomas (197), which opens 
the possibility of being used as a potential target for 
treatment of melanoma as well. Also, a subset of melanoma 
cells with features of stem cells and resistant to doxorubicin 
was found to express ABCB5, a novel member of the ABC 
superfamily of active drug transporters (198). This 
observation points to ABCB5 as a potential target to 
increase the poor efficacy of cytotoxic compounds in 
melanoma.  
 
These and other studies demonstrated that 
aggressive melanoma cells share many characteristics with 
embryonic progenitors.  Stem cells have a complex 
relationship with their microenvironment which exerts a 
crucial role in determining cell fate of embryonic 
progenitors. In cancer, the evidence accumulated over the 
last decades support a major role for stromal components in 
all stages of tumorigenesis including initiation, progression 
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and metastasis (199). The importance of the 
microenvironment on malignant progression was 
guessed by Stephen Paget over a century ago with the 
formulation of his “seed and soil” hypothesis (200). 
This hypothesis predicts that metastatic cancer cells will 
only colonize soils (organs) that are permissive to 
growth while other tissues will not support such growth 
(201). Lastly, a number of laboratories have shown that 
an embryonic microenvironment has the capacity to 
reverse the metastatic phenotype of cancer cells. Thus, 
several studies have documented that embryonic 
microenvironments of human embryonic stem cells, the 
zebrafish and the chick embryos (that are able to 
differentiate a stem cell lineage) reprogram aggressive 
melanoma cells towards a less aggressive phenotype 
(reviewed in ref. 195). Furthermore, these studies have 
uncovered Nodal, an embryonic morphogen belonging 
to the TGF-beta family, as an important factor for 
sustaining melanoma aggressiveness and plasticity. 
Nodal expression is regained in highly aggressive 
melanoma cell lines, invasive VGP melanoma and 
melanoma metastases, (202). These findings implicate 
Nodal as a new diagnostic marker in melanoma 
progression and a novel target for treatment of 
metastatic melanoma (195).  
 
8. CONCLUSIONS AND PERSPECTIVES  
 
A better understanding of melanoma biology has 
evolved over the past few years from molecular studies. 
Despite a wealth of data on chromosomal alterations, 
mutational analysis in key melanoma genes, epigenetic 
modifications, transcriptome profiles and interactions of 
melanoma cells with the microenvironment, the picture on 
the molecular biology of melanoma is far to be complete. 
Until today, tumor thickness and presence or absence of 
ulceration remain as the factors with best prognostic 
significance in primary cutaneous melanoma. In addition, 
melanoma is still a tumor refractory to chemotherapy 
treatment. Nevertheless, future advances in this area 
probably will improve our understanding of the 
heterogeneity of melanoma and will lead to a more precise 
taxonomy of this disease. Hopefully, the discovery of new 
individual signaling pathways known to be dysregulated in 
melanoma, such as Notch and Nodal, will favour the design 
and testing of novel therapeutic agents to treat advanced 
melanoma. 
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